Treatment of inflammatory bowel disease (IBD)
AssigneeGenentech, Inc.
InventorSheila Gujrathi
Life of this patent
Estimating the term…
Abstract
The present invention concerns treatment of IBD, especially ulcerative colitis (UC), with an antibody that binds to CD20.
Claims42
A method for treating moderate-severe inflammatory bowel disease (IBD) in a human subject comprising administering to the subject an effective amount of a CD20 antibody, wherein administration of the antibody results in a clinical response or disease remission.
A method for treating inflammatory bowel disease (IBD) in a human subject with active IBD comprising administering only one or two doses of a CD20 antibody to the subject, wherein disease remission or clinical response is achieved upon administration of the one or two doses of the CD20 antibody.
A method for treating inflammatory bowel disease (IBD) in a human subject with active IBD comprising administering to the subject an effective amount of a CD20 antibody and further comprising administering to the subject an effective amount of a second medicament selected from the group consisting of an aminosalicylate, an oral corticosteroid, 6-mercaptopurine (6-MP) and azathioprine.
A method for reducing a disease activity index (DAI) score in a human subject with active ulcerative colitis (UC) comprising administering a CD20 antibody to the subject in an amount effective to reduce DAI score.
An article of manufacture comprising:
- i. a container comprising a CD20 antibody;
- and
- ii. a package insert with instructions for treating inflammatory bowel disease (IBD) in a human subject, wherein the instructions indicate that an effective amount of the CD20 antibody is administered to the human subject.
Dependencies are inferred from the claim text.